CN119343345A - 四氢异喹啉异双官能bcl-xl降解剂 - Google Patents
四氢异喹啉异双官能bcl-xl降解剂 Download PDFInfo
- Publication number
- CN119343345A CN119343345A CN202380046254.4A CN202380046254A CN119343345A CN 119343345 A CN119343345 A CN 119343345A CN 202380046254 A CN202380046254 A CN 202380046254A CN 119343345 A CN119343345 A CN 119343345A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- optionally substituted
- formula
- compound
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263339253P | 2022-05-06 | 2022-05-06 | |
| US63/339,253 | 2022-05-06 | ||
| US202263398783P | 2022-08-17 | 2022-08-17 | |
| US63/398,783 | 2022-08-17 | ||
| US202263429862P | 2022-12-02 | 2022-12-02 | |
| US63/429,862 | 2022-12-02 | ||
| US202363449756P | 2023-03-03 | 2023-03-03 | |
| US63/449,756 | 2023-03-03 | ||
| US202363454545P | 2023-03-24 | 2023-03-24 | |
| US63/454,545 | 2023-03-24 | ||
| US202363457997P | 2023-04-07 | 2023-04-07 | |
| US63/457,997 | 2023-04-07 | ||
| PCT/US2023/021010 WO2023215482A1 (en) | 2022-05-06 | 2023-05-04 | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119343345A true CN119343345A (zh) | 2025-01-21 |
Family
ID=86688472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380046254.4A Pending CN119343345A (zh) | 2022-05-06 | 2023-05-04 | 四氢异喹啉异双官能bcl-xl降解剂 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240238423A9 (enExample) |
| EP (1) | EP4519259A1 (enExample) |
| JP (1) | JP2025517642A (enExample) |
| KR (1) | KR20250008772A (enExample) |
| CN (1) | CN119343345A (enExample) |
| AU (1) | AU2023264018A1 (enExample) |
| CA (1) | CA3251489A1 (enExample) |
| CL (1) | CL2024003362A1 (enExample) |
| IL (1) | IL316465A (enExample) |
| MX (1) | MX2024013537A (enExample) |
| PE (1) | PE20250007A1 (enExample) |
| TW (1) | TW202400589A (enExample) |
| WO (1) | WO2023215482A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026158623A1 (zh) * | 2025-01-26 | 2026-07-30 | 南京瑞初医药有限公司 | 蛋白降解剂及其应用 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023246924A1 (zh) * | 2022-06-24 | 2023-12-28 | 南京瑞初医药有限公司 | 苯并噻唑化合物及其应用 |
| KR20260111020A (ko) * | 2023-11-07 | 2026-07-14 | 트리라인 바이오사이언시스, 인크. | 테트라히드로이소퀴놀린 이종이작용성 bcl-xl 분해제 |
| AU2024378690A1 (en) * | 2023-11-07 | 2026-05-07 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
| IL327973A (en) * | 2023-11-07 | 2026-06-01 | Treeline Biosciences Inc | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
| AU2024409323A1 (en) * | 2023-12-18 | 2026-07-09 | Nanjing Reju Therapeutics Co., Ltd. | Nitrogen heterocyclic compound and use thereof |
| WO2026102147A1 (en) * | 2024-11-07 | 2026-05-15 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI571466B (zh) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
| CN103987711B (zh) | 2011-10-14 | 2016-08-24 | 艾伯维公司 | 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物 |
| CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| ES3041854T3 (en) | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| WO2020163823A2 (en) | 2019-02-08 | 2020-08-13 | University Of Florida Research Foundation, Incorporated | Therapeutic agents and methods of treatment |
| AU2020310147A1 (en) | 2019-07-10 | 2022-01-06 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| CN112707900B (zh) | 2019-10-24 | 2022-06-10 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| CA3163593A1 (en) | 2020-01-15 | 2021-07-22 | Guangrong Zheng | Therapeutic agents and methods of treatment |
| CA3173843A1 (en) | 2020-04-28 | 2021-11-04 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| JP2024505562A (ja) | 2021-02-02 | 2024-02-06 | レス ラボラトイレス セルビエル | 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法 |
| WO2023044046A1 (en) | 2021-09-17 | 2023-03-23 | Kymera Therapeutics, Inc. | Bcl-xl degraders and uses thereof |
| WO2023083194A1 (zh) * | 2021-11-09 | 2023-05-19 | 杭州格博生物医药有限公司 | Wee1蛋白激酶降解剂及其用途 |
-
2023
- 2023-05-04 PE PE2024002436A patent/PE20250007A1/es unknown
- 2023-05-04 WO PCT/US2023/021010 patent/WO2023215482A1/en not_active Ceased
- 2023-05-04 CA CA3251489A patent/CA3251489A1/en active Pending
- 2023-05-04 CN CN202380046254.4A patent/CN119343345A/zh active Pending
- 2023-05-04 KR KR1020247040564A patent/KR20250008772A/ko active Pending
- 2023-05-04 JP JP2024565273A patent/JP2025517642A/ja active Pending
- 2023-05-04 TW TW112116645A patent/TW202400589A/zh unknown
- 2023-05-04 AU AU2023264018A patent/AU2023264018A1/en active Pending
- 2023-05-04 US US18/143,454 patent/US20240238423A9/en active Pending
- 2023-05-04 EP EP23728483.1A patent/EP4519259A1/en active Pending
- 2023-05-04 IL IL316465A patent/IL316465A/en unknown
-
2024
- 2024-10-31 MX MX2024013537A patent/MX2024013537A/es unknown
- 2024-11-04 CL CL2024003362A patent/CL2024003362A1/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026158623A1 (zh) * | 2025-01-26 | 2026-07-30 | 南京瑞初医药有限公司 | 蛋白降解剂及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025517642A (ja) | 2025-06-10 |
| WO2023215482A1 (en) | 2023-11-09 |
| IL316465A (en) | 2024-12-01 |
| CA3251489A1 (en) | 2023-11-09 |
| CL2024003362A1 (es) | 2025-03-07 |
| EP4519259A1 (en) | 2025-03-12 |
| MX2024013537A (es) | 2024-12-06 |
| PE20250007A1 (es) | 2025-01-07 |
| US20240238423A9 (en) | 2024-07-18 |
| US20230390404A1 (en) | 2023-12-07 |
| KR20250008772A (ko) | 2025-01-15 |
| AU2023264018A1 (en) | 2024-11-07 |
| TW202400589A (zh) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12404285B2 (en) | KRAS G12D proteolysis targeting chimeras | |
| US12599672B2 (en) | KRAS proteolysis targeting chimeras | |
| KR20250008772A (ko) | 테트라하이드로이소퀴놀린 헤테로이작용성 bcl-xl 분해제 | |
| CN121889399A (zh) | Kras蛋白水解靶向嵌合体 | |
| TW202241906A (zh) | 吲唑化合物 | |
| CN115867554A (zh) | Brm靶向化合物和相关使用方法 | |
| KR20240028539A (ko) | 급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법 | |
| KR20230173234A (ko) | 인다졸계 화합물 및 관련된 사용 방법 | |
| TW201730182A (zh) | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 | |
| TW202330548A (zh) | 用於降解egfr激酶的化合物 | |
| TW202430187A (zh) | Ｂｃｌ６蛋白水解之調節劑及相關使用方法 | |
| JP2025516358A (ja) | テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 | |
| WO2022134641A1 (zh) | 芳香杂环类化合物、药物组合物及其应用 | |
| WO2022117882A2 (en) | Novel par-2 inhibitors | |
| EP4519272A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders | |
| CN119451957A (zh) | 1,8-萘啶-2-酮异双功能bcl6降解剂 | |
| WO2025101571A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders | |
| CN121752565A (zh) | 三环喹诺酮bcl6双官能降解剂 | |
| WO2025101588A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders | |
| CN114981270A (zh) | Mll1抑制剂和抗癌剂 | |
| IL325136A (en) | Pyrazolo-pyrimidinone compounds for use in methods for inhibiting kinase week1 a | |
| WO2025077773A1 (zh) | 新的i型拓扑异构酶抑制剂及其制备方法和用途 | |
| WO2026102147A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |